Dual-Targeted Hyaluronic Acid/Albumin Micelle-Like Nanoparticles for the Vectorization of Doxorubicin

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéuticagl
dc.contributor.authorCurcio, Manuela
dc.contributor.authorDíaz Gómez, Luis
dc.contributor.authorCirillo, Giuseppe
dc.contributor.authorNicoletta, Fiore Pasquale
dc.contributor.authorLeggio, Antonella
dc.contributor.authorLemma, Francesca
dc.date.accessioned2021-03-12T14:24:58Z
dc.date.available2021-03-12T14:24:58Z
dc.date.issued2021
dc.description.abstractDrug targeting of tumor cells is one of the great challenges in cancer therapy; nanoparticles based on natural polymers represent valuable tools to achieve this aim. The ability to respond to environmental signals from the pathological site (e.g., altered redox potential), together with the specific interaction with membrane receptors overexpressed on cancer cells membrane (e.g., CD44 receptors), represent the main features of actively targeted nanoparticles. In this work, redox-responsive micelle-like nanoparticles were prepared by self-assembling of a hyaluronic acid–human serum albumin conjugate containing cystamine moieties acting as a functional spacer. The conjugation procedure consisted of a reductive amination step of hyaluronic acid followed by condensation with albumin. After self-assembling, nanoparticles with a mean size of 70 nm and able to be destabilized in reducing media were obtained. Doxorubicin-loaded nanoparticles modulated drug release rate in response to different redox conditions. Finally, the viability and uptake experiments on healthy (BALB-3T3) and metastatic cancer (MDA-MB-231) cells proved the potential applicability of the proposed system as a drug vector in cancer therapygl
dc.description.peerreviewedSIgl
dc.description.sponsorshipL.D.-G. acknowledges Consellería de Cultura, Educación e Ordenación Universitaria for a postdoctoral fellowship (Xunta de Galicia, Spain; ED481B 2017/063)gl
dc.identifier.citationPharmaceutics 2021, 13(3), 304; https://doi.org/10.3390/pharmaceutics13030304gl
dc.identifier.doi10.3390/pharmaceutics13030304
dc.identifier.essn1999-4923
dc.identifier.urihttp://hdl.handle.net/10347/24738
dc.language.isoenggl
dc.publisherMDPIgl
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics13030304gl
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)gl
dc.rightsAtribución 4.0 Internacional
dc.rights.accessRightsopen accessgl
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHyaluronic acidgl
dc.subjectHuman serum albumingl
dc.subjectPolysaccharide-protein conjugategl
dc.subjectMicelle-like nanoparticlesgl
dc.subjectRedox-responsivegl
dc.subjectActive targetinggl
dc.subjectCancer therapygl
dc.titleDual-Targeted Hyaluronic Acid/Albumin Micelle-Like Nanoparticles for the Vectorization of Doxorubicingl
dc.typejournal articlegl
dc.type.hasVersionVoRgl
dspace.entity.typePublication
relation.isAuthorOfPublicationc2e6e565-8cb2-4c84-a7e4-c46c08852379
relation.isAuthorOfPublication.latestForDiscoveryc2e6e565-8cb2-4c84-a7e4-c46c08852379

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021_pharmaceutics_curcio_dual.pdf
Size:
3.26 MB
Format:
Adobe Portable Document Format
Description: